The Expression of Urokinase-type Plasminogen Activator and Its Receptor in Urinary Transitional Cell Carcinoma

Journal of Sichuan University (Medical Science)

Volumn 35, Issue 1, 2004, Pages 57-59

  Li, Yan Jiang ^a   Zheng, Bao Zhong ^a   Zhou, Zun Lin ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Transitional cell carcinoma; uPA; uPAR; Urinary system, neoplasm

Indexed keywords

UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY PELVIS CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; URETER CARCINOMA;

EID: 1642446682     PISSN: 1672173X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Dano K, Andresson PA, Grondahl-Hasen J, et al. Plasminogen activitor, tissue degradation and cancer. Adv Cancer Res, 1985; 44(1):139.
2. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: animbalance of positive and negative regulation. Cell, 1991; 64(2):327.
3. Macchione E, Epifano O, Stefanini M, et al. Urokinase redistribution from the secreted to cell-bound fraction in granulosa cells of rat preovulatory follicles. Biol Reprod, 2000; 62 (4):895.
4. Ossowski L. in vivo invasion of modified chorioallantoic membrane by tumor cell: the role of cell surface-bound urokinase. J Cell Biol, 1988; 107(6 pt 1):2437.
5. Hofmann R, Lehmer A, Hartung R, et al. Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer. J Urol, 1996; 155(3):858.